HomepageATYR • NASDAQ
add
aTyr Pharma Inc
Vorige slotkoers
$ 3,34
Dag-range
$ 3,27 - $ 3,42
Jaar-range
$ 1,42 - $ 4,66
Beurswaarde
292,82 mln. USD
Gem. volume
1,28 mln.
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 0,00 | — |
Bedrijfskosten | 3,59 mln. | 12,11% |
Netto inkomsten | -14,97 mln. | -1,40% |
Netto winstmarge | — | — |
Winst per aandeel | -0,18 | 28,00% |
EBITDA | -15,64 mln. | 0,88% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 72,12 mln. | -26,53% |
Totale activa | 96,83 mln. | -19,75% |
Totale passiva | 27,00 mln. | -10,55% |
Totaal aandelenvermogen | 69,83 mln. | — |
Uitstaande aandelen | 88,86 mln. | — |
Koers-boekwaardeverhouding | 4,02 | — |
Rendement op activa | -41,97% | — |
Rendement op kapitaal | -48,88% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -14,97 mln. | -1,40% |
Operationele kasstroom | -13,13 mln. | -18,71% |
Kasstroom uit beleggingen | -6,08 mln. | -134,15% |
Kasstroom uit financiering | 18,84 mln. | 212,21% |
Nettomutatie in liquide middelen | -378,00K | -102,96% |
Vrije kasstroom | -7,83 mln. | -52,29% |
Over
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Opgericht
1 jan 2005
Website
Werknemers
61
